GW Pharmaceuticals PLC- (GWPH) Lifted to “Buy” at Goldman Sachs Group

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by equities researchers at Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued on Thursday, Marketbeat.com reports. The brokerage presently has a $174.00 price objective on the biopharmaceutical company’s stock. Goldman Sachs Group’s target price indicates a potential upside of 33.01% from the stock’s current price.

A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Monday, December 4th. Bank of America decreased their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a report on Tuesday, November 14th. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cowen restated an “outperform” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Finally, Leerink Swann restated an “outperform” rating and set a $153.00 price objective (down previously from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and a consensus target price of $148.78.

GW Pharmaceuticals PLC- (NASDAQ GWPH) traded up $6.84 on Thursday, hitting $130.82. 937,126 shares of the company were exchanged, compared to its average volume of 332,752. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.47 and a current ratio of 7.59. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $136.95.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in GW Pharmaceuticals PLC- by 0.4% during the second quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 18 shares during the last quarter. IHT Wealth Management LLC increased its stake in shares of GW Pharmaceuticals PLC- by 18.0% in the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares in the last quarter. Advisor Group Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 10.7% in the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 8.5% in the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 162 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its stake in shares of GW Pharmaceuticals PLC- by 18.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 581 shares in the last quarter. Institutional investors and hedge funds own 81.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Lifted to “Buy” at Goldman Sachs Group” was originally reported by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/14/gw-pharmaceuticals-plc-gwph-lifted-to-buy-at-goldman-sachs-group.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).